

CORRIGENDUM

M Pai, K Elwood. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: Dynamic patterns and interpretational challenges. *Can Respir J* 2012;2:81-3.

The data presented in selected cells of the table that appeared in this editorial were shifted. The correct table is presented below:

TABLE 1
Serial testing studies of interferon-gamma release assays in health care workers (HCWs) in low and intermediate incidence countries

Author (reference), year, country	Duration between testing	Conversion, n/N (%)		IGRA reversions*, n/N (%)
		Tuberculin skin test	IGRA*	
Joshi et al (15), 2012, USA	2 to 30 days	N/A	N/A	18/45 (40)
Rafiza et al (16), 2012, Malaysia	1 year	N/A	69/703 (9.8)	14/59 (23.7)
Fong et al (17), 2012, USA	1 year or 1 to 6 months for repeat of positive IGRA	N/A	52/1857 (2.8)	8/10 (80) [†]
Torres Costa et al (18), 2011, Portugal	1 year	61/199 (30.7) 4/188 (2.1)	Reversion rates: 51 /462 (11)	46/208 (22.1)
Schablon et al (19), 2010, Germany	High-risk HCWs tested annually, all others evaluated every other year	N/A	15/245 (6.1)	13/42 (32.6)
Ringshausen et al (20), 2010, Germany	18 weeks	N/A	3/162 (1.9)	6/18 (33.3)
Park et al (21), 2010, South Korea	1 year	N/A	14/244 (5.7)	N/A
Lee et al (22), 2009, South Korea	1 year	16/75 (21.3)	21/146 (14.4)	N/A
Chee et al (23), 2009, Singapore	1 year	0/18 (Note: denominator includes only baseline concordant positives)	9/182 (4.9)	N/A
Yoshiyama et al (24), 2009, Japan	2 and 4 years	N/A	5/277 (1.8)	13/32 (41)
Pollock et al (25), 2008, USA	1 to 7 months	N/A	2/43 (4.6). Selected HCWs at 'increased risk' and negative at baseline	N/A

*All conversions/reversions using simple negative/positive; [†] Testing was performed among individuals with positive QuantiFERON-TB (Cellestis Ltd, Australia) results close to the cut-off point. IGRA Interferon-gamma release assay; N/A Not available